

COGNITIVE

Selank

TP-7 Tuftsin Analogue

Heptapeptide anxiolytic nootropic. GABAergic tone modulation without sedation or dependence.

MECHANISM

GABAergic modulation; BDNF and enkephalin upregulation

DOSAGE

250–500 mcg/day SC or intranasal

HALF-LIFE

<10 min plasma (central effects persist)

FORMAT

Lyophilised powder

BATCH

NU-SEL-2148

LOT

542148

CAS

129954-34-3

FORMULA

C33H57N11O9

ISSUED

2025-08-08

RETEST

2026-08-08

OVERVIEW

Selank is a heptapeptide anxiolytic (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics, Russian Academy of Sciences, as a tuftsin analogue. Unlike benzodiazepines, it modulates GABAergic tone without sedation, dependence, or cognitive blunting.

MECHANISM OF ACTION

GABAergic modulation; BDNF and enkephalin upregulation

KEY RESEARCH BENEFITS

- Anxiolytic without sedation or dependence
- BDNF upregulation — neuroplasticity enhancement
- Improved working memory and learning
- Stable mood without emotional blunting
- Antiviral immunomodulatory properties

RESEARCH NOTES

Russian Phase III trials (N = 60+) show significant GAD symptom reduction vs placebo. BDNF serum elevation of 35% documented. Registered medicine in Russia since 2009.

STORAGE & STABILITY

Lyophilised: -20 °C, stable >=24 months. Reconstituted: 2–8 °C, use within 14 days.